| 2025 |
Tiruye, T., Jay, A., Higgs, B., O'Callaghan, M., FitzGerald, L., Moretti, K., . . . Beckmann, K. (2025). Urinary and colorectal procedures following prostate cancer treatment. BJU International, 135(S2), 98. |
| 2025 |
Tiruye, T., Duko, B., Mekonnen, L., Ward, P., Nguyen, T. H. H. D., Byrne, S., . . . Beckmann, K. (2025). Cancer Burden Attributable to Potentially Modifiable Risk Factors in Australia. Cancers, 17(19), 1-30. DOI Scopus1 WoS1 |
| 2025 |
Dars, S., Tiruye, T., Roder, D., Banwell, H. A., Olver, I., & Beckmann, K. (2025). Patterns and factors associated with podiatry service use among colorectal cancer patients following chemotherapy in South Australia: focus on Chemotherapy-Induced Peripheral Neuropathy (CIPN). Journal of Multidisciplinary Healthcare, 18, 6361-6372. DOI |
| 2025 |
Beckmann, K., Kearney, B. J., Shanmuganathan, N., Yeung, D., & Hughes, T. (2025). Disease-specific survival for people with chronic myeloid leukaemia, South Australia, 1980–2020: a retrospective cohort study. Medical Journal of Australia, 223(11), 3 pages. DOI |
| 2025 |
Irenaeus, S., Garmo, H., Gedeborg, R., Ahlberg, M., Robinson, D., Stattin, P., & Beckmann, K. (2025). Potential gains from radical treatment of men with prostate cancer according to life expectancy. Bjui Compass, 6(9), 9 pages. DOI |
| 2025 |
Lin, E., Garmo, H., Beckmann, K., Bratt, O., Akre, O., Stattin, P., & Gedeborg, R. (2025). Prostate cancer characteristics in fathers and risk of early onset high-risk prostate cancer in sons. International Journal of Cancer, online, 7 pages. DOI Scopus1 WoS1 Europe PMC1 |
| 2025 |
Lin, E., Garmo, H., Beckmann, K., Bratt, O., Stattin, P., & Gedeborg, R. (2025). Family History of Early Onset or Lethal Prostate Cancer and the Risk of Prostate Cancer Death in Sweden. Cancer Epidemiology Biomarkers and Prevention, 34(9), 1585-1592. DOI |
| 2025 |
Jayasinghe, D., Pham, V. V. H., Beckmann, K., Benyamin, B., & Lee, S. H. (2025). Analyzing complex traits and diseases using GxE PRS: genotype-environment interaction in polygenic risk score models. Journal of Human Genetics, 70(11), 547-556. DOI |
| 2025 |
Monroy-Iglesias, M. J., Thavarajah, R., Beckmann, K., Josephs, D. H., Irshad, S., Karagiannis, S. N., . . . Santaolalla, A. (2025). Effects of vitamin D on COVID-19 risk and hospitalisation in the UK biobank. Plos One, 20(7 July), 14 pages. DOI Europe PMC1 |
| 2025 |
Charlick, M., Murphy, M., Murphy, B., Ettridge, K., O'Callaghan, M., Sara, S., . . . Beckmann, K. (2025). Sexual wellbeing support for men with prostate cancer: a qualitative study with patients. Translational Andrology and Urology, 14(4), 913-927. DOI Scopus1 WoS1 Europe PMC1 |
| 2025 |
Ng, H. S., Johansen, C., Li, M., Roder, D., Beckmann, K., & Koczwara, B. (2025). Patterns of medication use following breast cancer diagnosis: an Australian population-based study. SUPPORTIVE CARE IN CANCER, 33(8), 11 pages. DOI |
| 2025 |
Tiruye, T., Jay, A., O'Callaghan, M., FitzGerald, L. M., Roder, D., & Beckmann, K. (2025). Post‑prostatectomy rehospitalisation rates and risk factors in South Australian men with prostate cancer: evidence from linked data. International Urology and Nephrology, online, 1-10. DOI |
| 2025 |
Tiruye, T., Higgs, B., O'Callaghan, M., FitzGerald, L. M., Roder, D., & Beckmann, K. (2025). Socioeconomic and Geographic Disparities in Anorectal and Urinary Procedures Following Radiotherapy for Prostate Cancer. Cancer Medicine, 14(15, article no. e71135), 1-10. DOI Europe PMC1 |
| 2025 |
Bott, R., Zylstra, J., Knight, W., Whyte, G. P., Lane, A. M., Moss, C., . . . Pate, J. (2025). Prehabilitation of Patients With Oesophageal Malignancy Undergoing Peri-Operative Treatment (Pre-EMPT): Outcomes From a Prospective Controlled Trial. Journal of Surgical Oncology, 131(8), 1508-1520. DOI Scopus3 WoS2 Europe PMC3 |
| 2025 |
Charlick, M., Ettridge, K., Tiruye, T., O'Callaghan, M., Sara, S., Jay, A., & Beckmann, K. (2025). Improving sexual well-being support for men with prostate cancer: the health professional perspective. European Journal of Cancer Care, 2025(1, article no. 2875201), 1-11. DOI |
| 2025 |
Charlick, M., Tiruye, T., Ettridge, K., O'Callaghan, M., Jay, A., & Beckmann, K. (2025). Use of erectile dysfunction treatments after prostate cancer treatment and their perceived impact on men's sex life: an analysis of patient reported outcome survey data. BMC Urology, 25(21), 1-11. DOI Scopus1 WoS1 Europe PMC2 |
| 2025 |
Tiruye, T., Jay, A., Higgs, B., O'Callaghan, M., FitzGerald, L. M., Moretti, K., . . . Beckmann, K. (2025). Comparing post‑treatment urinary and colorectal procedures in prostate cancer patients using population‑based linked data. International Urology and Nephrology, 57(4), 1189-1198. DOI Scopus2 WoS2 Europe PMC2 |
| 2025 |
Ng, H. S., Johansen, C., Li, M., Roder, D., Beckmann, K., & Koczwara, B. (2025). Patterns of medication use following breast cancer diagnosis: an Australian population-based study.. Supportive Care in Cancer, 33(8, article no. 668), 1-11. DOI |
| 2024 |
Tiruye, T., Roder, D., FitzGerald, L. M., O'Callaghan, M., Moretti, K., & Beckmann, K. (2024). Utility of prescription-based comorbidity indices for predicting mortality among Australian men with prostate cancer. Cancer Epidemiology, 88(102516), 1-7. DOI Scopus7 WoS7 Europe PMC5 |
| 2024 |
Tiruye, T., O'Callaghan, M., FitgGerald, L. M., Moretti, K., Jay, A., Higgs, B., . . . Beckmann, K. (2024). Medication-based comorbidity measures and prostate cancer treatment selection. Clinical Genitourinary Cancer, 22(2), 599-609. DOI Scopus8 WoS8 Europe PMC6 |
| 2024 |
Tiruye, T., Roder, D., FitzGerald, L. M., O'Callaghan, M., Moretti, K., Caughey, G. E., & Beckmann, K. (2024). Impact of comorbidities on prostate cancer‐specific mortality: A population‐based cohort study. The Prostate, 84(12), 1138-1145. DOI Scopus10 WoS9 Europe PMC9 |
| 2024 |
Tiruye, T., Hiwase, M., Charlick, M., O'Callaghan, M., Khalid, A., Li, M., . . . Beckmann, K. (2024). Temporal trends in medication and service use patterns for mental health issues among men with prostate cancer. Psychooncology, 33(7), e6369-1-e6369-11. DOI Scopus1 WoS2 |
| 2024 |
Ong, W. L., Krishnaprasad, K., Bensley, J., Steeper, M., Beckmann, K., Breen, S., . . . Millar, J. (2024). Population-based prostate cancer outcomes registries - what have we learned and where are we heading?. BJU International, 134(S2), 9-11. DOI Scopus5 WoS5 Europe PMC4 |
| 2024 |
Charlick, M., Tiruye, T., Ettridge, K., O'Callaghan, M., Sara, S., Jay, A., & Beckmann, K. (2024). Prostate cancer related sexual dysfunction and barriers to help seeking: a scoping review. Psycho-oncology, 33(8), 1-13. DOI Scopus6 WoS6 Europe PMC6 |
| 2024 |
Jayasinghe, D., Eshetie, S., Beckmann, K., Benyamin, B., & Lee, S. H. (2024). Advancements and limitations in polygenic risk score methods for genomic prediction: a scoping review. Human Genetics, 143(12), 1401-1431. DOI Scopus10 WoS11 Europe PMC16 |
| 2024 |
Tiruye, T., & Beckmann, K. (2024). Communicating prostate cancer outcomes data to consumers– A brief communication. Urologic Oncology Seminars and Original Investigations, 42(10), 331-331.e11. DOI Scopus2 WoS1 Europe PMC1 |
| 2024 |
Jayasinghe, D., Momin, M. M., Beckmann, K., Hyppönen, E., Benyamin, B., & Lee, S. H. (2024). Mitigating type 1 error inflation and power loss in GxE PRS: Genotype–environment interaction in polygenic risk score models. Genetic Epidemiology, 48(2), 85-100. DOI Scopus6 WoS7 Europe PMC8 |
| 2024 |
Tiruye, T. Y., O'Callaghan, M., Ettridge, K., Moretti, K., Jay, A., Higgs, B., . . . Beckmann, K. (2024). Clinical and functional outcomes for risk-appropriate treatments for prostate cancer. BJUI Compass, 5(1), 109-120. DOI Scopus10 WoS10 Europe PMC7 |
| 2023 |
Tiruye, T., Ettridge, K., O'Callaghan, M., Moretti, K., Jay, A., Higgs, B., . . . Beckmann, K. (2023). Reporting real-world data on prostate cancer treatment outcomes to consumers: the prostate cancer report card. European Journal of Cancer Care, 2023(6660371), 1-12. DOI Scopus6 WoS6 |
| 2023 |
Tiruye, T., Roder, D., FitzGerald, L. M., O'Callaghan, M., Morreti, K., & Beckmann, K. (2023). Prognostic value of comorbidity measures among Australian men with non-metastatic prostate cancer. Cancer Epidemiology, 87(102482), 1-6. DOI Scopus6 WoS5 Europe PMC1 |
| 2023 |
Tiruye, T., David, R., O'Callaghan, M., FitzGerald, L. M., Higgs, B., Kahokehr, A. A., . . . Beckmann, K. (2023). Risk of secondary malignancy following radiation therapy for prostate cancer. Scientific Reports, 23(20083), 1-10. DOI Scopus15 WoS15 Europe PMC12 |
| 2023 |
Tiruye, T., O'Callaghan, M., Ettridge, K., Jay, A., Santoro, K., Moretti, K., & Beckmann, K. (2023). Factors impacting on sexual function among men on active surveillance for prostate cancer. The Prostate, 83(7), 678-687. DOI Scopus10 WoS8 Europe PMC7 |
| 2023 |
Dars, S., Buckley, E., Beckmann, K., Roder, D., & Banwell, H. (2023). Development of the consensus-based recommendations for Podiatry care of Neuropathy In Cancer Survivors (PodNICS): a Delphi consensus study of Australian podiatrists. Journal of Foot and Ankle Research, 16(1), 1-14. DOI Scopus2 WoS2 Europe PMC1 |
| 2023 |
Beckmann, K. R., O'Callaghan, M. E., Vincent, A. D., Moretti, K. L., & Brook, N. R. (2023). Clinical outcomes for men with positive surgical margins after radical prostatectomy—results from the South Australian Prostate Cancer Clinical Outcomes Collaborative community-based registry. Asian Journal of Urology, 10(4), 502-511. DOI Scopus5 WoS5 Europe PMC7 |
| 2023 |
Beckmann, K., Cahill, D., Brown, C., Van Hemelrijck, M., & Kinsella, N. (2023). Developing a consensus statement for psychosocial support in active surveillance for prostate cancer. Bjui Compass, 4(1), 104-113. DOI Scopus3 WoS2 Europe PMC4 |
| 2023 |
Westerberg, M., Beckmann, K., Gedeborg, R., Irenaeus, S., Holmberg, L., Garmo, H., & Stattin, P. (2023). Choice of imputation method for missing metastatic status affected estimates of metastatic prostate cancer incidence. Journal of Clinical Epidemiology, 155, 22-30. DOI Scopus3 WoS3 Europe PMC3 |
| 2023 |
Beckmann, K., Santaolalla, A., Sugimoto, M., Carroll, P., Rubio, J., Villers, A., . . . Elhage, O. (2023). Risk of progression following a negative biopsy in prostate cancer active surveillance. Prostate Cancer and Prostatic Diseases, 26(2), 403-409. DOI Scopus4 WoS4 Europe PMC4 |
| 2022 |
Monroy-Iglesias, M. J., Crescioli, S., Beckmann, K., Le, N., Karagiannis, S. N., Van Hemelrijck, M., & Santaolalla, A. (2022). Antibodies as biomarkers for cancer risk: A systematic review. Clinical and Experimental Immunology, 209(1), 46-63. DOI Scopus22 WoS19 Europe PMC19 |
| 2022 |
Beckmann, K. R., Bangma, C. H., Helleman, J., Bjartell, A., Carroll, P. R., Morgan, T., . . . Roobol, M. J. (2022). Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate, 82(7), 876-879. DOI Scopus2 WoS2 Europe PMC4 |
| 2022 |
Beckmann, K., Crawley, D., Nelson, W. G., Platz, E. A., Selvin, E., Van Hemelrijck, M., & Rohrmann, S. (2022). Hormonal patterns in men with prediabetes and diabetes in NHANES III: possible links with prostate cancer. Cancer Causes and Control, 33(3), 429-440. DOI Scopus4 WoS5 Europe PMC4 |
| 2022 |
Shah, S., Beckmann, K., Van Hemelrijck, M., Challacombe, B., Popert, R., Dasgupta, P., . . . Santaolalla, A. (2022). Correction to: Guy’s and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database (BMC Cancer, (2021), 21, 1, (573), 10.1186/s12885-021-08255-z). BMC Cancer, 22(1), 1 page. DOI |
| 2022 |
Zylstra, J., Whyte, G. P., Beckmann, K., Pate, J., Santaolalla, A., Gervais-Andre, L., . . . Davies, A. (2022). Exercise prehabilitation during neoadjuvant chemotherapy may enhance tumour regression in oesophageal cancer: results from a prospective non-randomised trial. British Journal of Sports Medicine, 56(7), 402-409. DOI Scopus55 WoS57 Europe PMC47 |
| 2022 |
Bundred, J. R., Michael, S., Stuart, B., Cutress, R. I., Beckmann, K., Holleczek, B., . . . Bundred, N. J. (2022). Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis. BMJ, 378(e070346), 11 pages. DOI Scopus92 WoS87 Europe PMC73 |
| 2022 |
Tiruye, T., O’Callaghan, M., Moretti, K., Jay, A., Higgs, B., Santoro, K., . . . Beckmann, K. (2022). Patient-reported functional outcome measures and treatment choice for prostate cancer. BMC Urology, 22(1), 1-11. DOI Scopus13 WoS13 Europe PMC12 |
| 2022 |
Radbone, C., Beckmann, K., Roder, D., O'Callaghan, M., Moretti, K., Fitzgerald, L., & Buckley, L. (2022). Multi-jurisdictional Prostate cancer registry linkage. International Journal of Population Data Science, 7(3, article no. 2101), 1. DOI |
| 2022 |
Beckmann, K., Kearney, B. J., Yeung, D., Hiwase, D., Li, M., & Roder, D. M. (2022). Changes in five-year survival for people with acute leukaemia in South Australia, 1980-2016. Medical Journal of Australia, 216(6), 296-302. DOI Scopus9 WoS9 Europe PMC9 |
| 2021 |
Beckmann, K., Selva-Nayagam, S., Olver, I., Miller, C., Buckley, E. S., Powell, K., . . . Oehler, M. K. (2021). Carcinosarcomas of the uterus: prognostic factors and impact of adjuvant treatment. Cancer Management and Research, 13, 4633-4645. DOI Scopus7 WoS7 Europe PMC5 |
| 2021 |
Beckmann, K., Santaolalla, A., Helleman, J., Carroll, P., Ha Chung, B., Shiong Lee, L., . . . Elhage, O. (2021). Comparison of characteristics, follow-up and outcomes of active surveillance for prostate cancer according to ethnicity in the GAP3 Global Consortium Database. European Urology Open Science, 34, 47-54. DOI Scopus2 WoS4 Europe PMC4 |
| 2021 |
Tomer, A., Nieboer, D., Roobol, M. J., Bjartell, A., Steyerberg, E. W., Rizopoulos, D., . . . Helleman, J. (2021). Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. BJU International, 127(1), 96-107. DOI Scopus21 Europe PMC23 |
| 2021 |
Singh, S., Sandhu, P., Beckmann, K., Santaolalla, A., Dewan, K., Clovis, S., . . . Elhage, O. (2021). Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment. BJU International, 128(1), 72-78. DOI Scopus6 WoS6 Europe PMC3 |
| 2021 |
Bott, R. K., Beckmann, K., Zylstra, J., Wilkinson, M. J., Knight, W. R. C., Baker, C. R., . . . Davies, A. R. (2021). Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins. Acta Oncologica, 60(5), 672-680. DOI Scopus4 WoS5 Europe PMC5 |
| 2021 |
Monroy‐iglesias, M. J., Moss, C., Beckmann, K., Hammar, N., Walldius, G., Bosco, C., . . . Santaolalla, A. (2021). Serum total bilirubin and risk of cancer: A swedish cohort study and meta‐analysis. Cancers, 13(21), 13 pages. DOI Scopus20 WoS16 Europe PMC21 |
| 2021 |
Beckmann, K., Cahill, D., Brown, C., van Hemelrijck, M., & Kinsella, N. (2021). Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer. Translational Andrology and Urology, 10(6), 2728-2736. DOI Scopus14 WoS14 Europe PMC14 |
| 2021 |
Shah, S., Beckmann, K., Van Hemelrijck, M., Challacombe, B., Popert, R., Dasgupta, P., . . . Santaolalla, A. (2021). Guy’s and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database. BMC Cancer, 21(1), 12 pages. DOI Scopus3 WoS2 Europe PMC1 |
| 2021 |
Beckmann, K., Garmo, H., Lissbrant, I. F., & Stattin, P. (2021). The value of real-world data in understanding prostate cancer risk and improving clinical care: Examples from Swedish registries. Cancers, 13(4), 1-19. DOI Scopus13 WoS10 Europe PMC12 |
| 2021 |
Kum, F., Beckmann, K., Aya, H., Singh, S., Sandhu, P., Sra, S., . . . Elhage, O. (2021). Presentation, follow-up, and outcomes among African/Afro-Caribbean men on active surveillance for prostate cancer: experiences of a high-volume UK centre. Prostate Cancer and Prostatic Diseases, 24(2), 549-557. DOI Scopus3 WoS3 Europe PMC2 |
| 2021 |
Monroy-Iglesias, M. J., Russell, B., Crawley, D., Allen, N. E., Travis, R. C., Perez-Cornago, A., . . . Beckmann, K. (2021). Metabolic syndrome biomarkers and prostate cancer risk in the UK Biobank. International Journal of Cancer, 148(4), 825-834. DOI Scopus33 WoS34 Europe PMC33 |
| 2020 |
Beckmann, K., Garmo, H., Nilsson, P., Franck Lissbrant, I., Widmark, A., & Stattin, P. (2020). Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998–2016. Acta Oncologica, 59(5), 549-557. DOI Scopus13 WoS13 Europe PMC10 |
| 2020 |
Beckmann, K., Garmo, H., Lindahl, B., Holmberg, L., Stattin, P., Adolfsson, J., . . . Van Hemelrijck, M. (2020). Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study. Prostate Cancer and Prostatic Diseases, 23(3), 527-533. DOI Scopus15 WoS16 Europe PMC16 |
| 2020 |
Santaolalla, A., Beckmann, K., Kibaru, J., Josephs, D., Van Hemelrijck, M., & Irshad, S. (2020). Association Between Vitamin D and Novel SARS-CoV-2 Respiratory Dysfunction – A Scoping Review of Current Evidence and Its Implication for COVID-19 Pandemic. Frontiers in Physiology, 11(564387), 18 pages. DOI Scopus30 WoS27 Europe PMC24 |
| 2020 |
Parker, J., Crawley, D., Garmo, H., Lindahl, B., Styrke, J., Adolfsson, J., . . . Beckmann, K. (2020). Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control Study. Frontiers in Oncology, 10(571838), 8 pages. DOI Scopus4 WoS4 Europe PMC4 |
| 2020 |
Bott, R. K., Beckmann, K., Zylstra, J., Wilkinson, M. J., Knight, W. R. C., Baker, C. R., . . . Zeki, S. S. (2020). Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin. British Journal of Surgery, 107(13), 1801-1810. DOI Scopus9 WoS10 Europe PMC7 |
| 2020 |
Burdett, N., Hsu, K., Xiong, L., Tapia-Rico, G., Beckmann, K., Karapetis, C., & Brown, M. P. (2020). Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune-related adverse events after immune checkpoint inhibitor therapy. Asia-Pacific Journal of Clinical Oncology, 16(2), 139-145. DOI Scopus13 WoS12 Europe PMC10 |
| 2020 |
Morias, S., Buckley, E., Beckmann, K., O'Callaghan, M., Borg, M., & Short, M. (2020). Variation in radiotherapy patterns of care in the radical treatment of South Australian men with non-metastatic prostate cancer between 2005–2015. Radiotherapy and Oncology, 145, 138-145. DOI Scopus3 WoS3 Europe PMC2 |
| 2019 |
Beckmann, K., O'Callaghan, M., Vincent, A., Cohen, P., Borg, M., Roder, D., . . . Moretti, K. (2019). Extent and predictors of grade upgrading and downgrading in an Australian cohort according to the new prostate cancer grade groupings.. Asian journal of urology, 6(4), 321-329. DOI Scopus10 WoS10 Europe PMC10 |
| 2019 |
Van Hemelrijck, M., Ji, X., Kattan, M. W., Helleman, J., Roobol, M. J., Nieboer, D., . . . Bruinsma, S. (2019). Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 75(3), 523-531. DOI Scopus73 WoS81 Europe PMC68 |
| 2019 |
Drost, F. J. H., Nieboer, D., Morgan, T. M., Carroll, P. R., Roobol, M. J., Trock, B., . . . Helleman, J. (2019). Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. European Urology, 76(5), 693-702. DOI Scopus23 WoS22 Europe PMC20 |
| 2019 |
Beckmann, K., Crawley, D., Nordström, T., Aly, M., Olsson, H., Lantz, A., . . . Van Hemelrijck, M. (2019). Association between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results. JAMA Network Open, 2(11), 12 pages. DOI Scopus17 WoS19 Europe PMC20 |
| 2019 |
Ahlberg, M. S., Adami, H. O., Beckmann, K., Bertilsson, H., Bratt, O., Cahill, D., . . . Bill-Axelson, A. (2019). PCASTt/SPCG-17-A randomised trial of active surveillance in prostate cancer: Rationale and design. BMJ Open, 9(8), 7 pages. DOI Scopus20 WoS23 Europe PMC16 |
| 2019 |
Beckmann, K., Kinsella, N., Olsson, H., Wallerstedt Lantz, A., Nordstrom, T., Aly, M., . . . Van Hemelrijck, M. (2019). Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?. BMC Urology, 19(1), 8 pages. DOI Scopus1 Europe PMC1 |
| 2019 |
Kinsella, N., Beckmann, K., Cahill, D., Elhage, O., Popert, R., Cathcart, P., . . . Van Hemelrijck, M. (2019). A Single Educational Seminar Increases Confidence and Decreases Dropout from Active Surveillance by 5 Years After Diagnosis of Prostate Cancer. European Urology Oncology, 2(4), 464-470. DOI Scopus9 WoS8 Europe PMC9 |
| 2019 |
Beckmann, K., Russell, B., Josephs, D., Garmo, H., Haggstrom, C., Holmberg, L., . . . Adolfsson, J. (2019). Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: A population-based case-control study. BMC Cancer, 19(1), 9 pages. DOI Scopus13 WoS13 Europe PMC12 |
| 2019 |
Wu, W. Y. Y., Tabar, L., Tot, T., Fann, C. Y., Yen, A. M. F., Chen, S. L. S., . . . Chen, H. H. (2019). Imaging Biomarkers as Predictors for Breast Cancer Death. Journal of Oncology, 2019(2087983), 12 pages. DOI Scopus13 WoS13 Europe PMC9 |
| 2019 |
Beckmann, K., Garmo, H., Adolfsson, J., Bosco, C., Johansson, E., Robinson, D., . . . Van Hemelrijck, M. (2019). Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer. European Urology, 75(4), 676-683. DOI Scopus13 WoS12 Europe PMC10 |
| 2019 |
Tabár, L., Dean, P. B., Chen, T. H. H., Yen, A. M. F., Chen, S. L. S., Fann, J. C. Y., . . . Duffy, S. W. (2019). The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer, 125(4), 515-523. DOI Scopus204 WoS183 Europe PMC142 |
| 2018 |
Russell, B., Garmo, H., Beckmann, K., Stattin, P., Adolfsson, J., & Van Hemelrijck, M. (2018). A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0. Plos One, 13(4), 10 pages. DOI Scopus7 WoS6 Europe PMC7 |
| 2018 |
Hsieh, A. H. C., Tahkar, H., Koczwara, B., Kichenadasse, G., Beckmann, K., Karapetis, C., & Sukumaran, S. (2018). Pre-treatment serum lactate dehydrogenase as a biomarker in small cell lung cancer. Asia Pacific Journal of Clinical Oncology, 14(2), e64-e70. DOI Scopus12 WoS13 Europe PMC14 |
| 2018 |
Tabar, L., Chen, T. H. H., Yen, A. M. F., Chen, S. L. S., Fann, J. C. Y., Chiu, S. Y. H., . . . Duffy, S. W. (2018). Effect of mammography screening on mortality by histological grade. Cancer Epidemiology Biomarkers and Prevention, 27(2), 154-157. DOI Scopus34 WoS30 Europe PMC28 |
| 2018 |
Beckmann, K., O'Callaghan, M., Vincent, A., Roder, D., Millar, J., Evans, S., . . . Moretti, K. (2018). Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy. ANZ Journal of Surgery, 88(3), E183-E188. DOI Scopus2 WoS2 Europe PMC2 |
| 2018 |
Lu, T. C., Moretti, K., Beckmann, K., Cohen, P., & O Callaghan, M. (2018). ISUP Group 4 – a Homogenous Group of Prostate Cancers?. Pathology and Oncology Research, 24(4), 921-925. DOI Scopus11 WoS11 Europe PMC8 |
| 2017 |
Campbell, J., O'Callaghan, M., Raymond, E., Vincent, A., Beckmann, K., Roder, D., . . . Moretti, K. (2017). Tools for Predicting Clinical and Patient-reported Outcomes in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Systematic Review of Prognostic Accuracy and Validity. Clinical Genitourinary Cancer, 15(6), 629-634. DOI Scopus7 WoS5 Europe PMC6 |
| 2017 |
O'Callaghan, M., Raymond, E., Campbell, J., Vincent, A., Beckmann, K., Roder, D., . . . Moretti, K. (2017). Tools for predicting patient-reported outcomes in prostate cancer patients undergoing radical prostatectomy: A systematic review of prognostic accuracy and validity. Prostate Cancer and Prostatic Diseases, 20(4), 378-388. DOI Scopus21 WoS18 Europe PMC18 |
| 2017 |
Campbell, J., Raymond, E., O'Callaghan, M., Vincent, A., Beckmann, K., Roder, D., . . . Moretti, K. (2017). Optimum Tools for Predicting Clinical Outcomes in Prostate Cancer Patients Undergoing Radical Prostatectomy: A Systematic Review of Prognostic Accuracy and Validity. Clinical Genitourinary Cancer, 15(5), e827-e834. DOI Scopus23 WoS22 Europe PMC19 |
| 2017 |
Beckmann, K., Vincent, A., O'Callaghan, M., Cohen, P., Chang, S., Borg, M., . . . Moretti, K. (2017). Oncological outcomes in an Australian cohort according to the new prostate cancer grading groupings. BMC cancer, 17(1), 537. DOI Scopus3 WoS3 Europe PMC2 |
| 2017 |
Roder, D., Farshid, G., Kollias, J., Koczwara, B., Karapetis, C., Adams, J., . . . Price, T. (2017). Female breast cancer management and survival: the experience of major public hospitals in South Australia over 3 decades-trends by age and in the elderly. Journal of Evaluation in Clinical Practice, 23(6), 1433-1443. DOI Scopus6 WoS7 Europe PMC5 |
| 2017 |
Roder, D., Farshid, G., Gill, G., Kollias, J., Koczwara, B., Karapetis, C., . . . Beckmann, K. (2017). Breast cancer screening-opportunistic use of registry and linked screening data for local evaluation. Journal of Evaluation in Clinical Practice, 23(3), 508-516. DOI Scopus4 WoS2 Europe PMC2 |
| 2017 |
Buckley, E., Farshid, G., Gill, G., Kollias, J., Koczwara, B., Karapetis, C., . . . Roder, D. (2017). Assessing impact of organised breast screening across small residential areas-development and internal validation of a prediction model. European Journal of Cancer Care, 26(4), e12673-1-e12673-8. DOI |
| 2017 |
Raymond, E., O'Callaghan, M., Campbell, J., Vincent, A., Beckmann, K., Roder, D., . . . Moretti, K. (2017). An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review. Radiation Oncology, 12(1), 56-1-56-20. DOI Scopus15 WoS15 Europe PMC10 |
| 2017 |
Beckmann, K., Moore, J., Wattchow, D., Young, G., & Roder, D. (2017). Short-term outcomes after surgical resection for colorectal cancer in South Australia. Journal of evaluation in clinical practice, 23(2), 316-324. DOI Scopus16 WoS16 Europe PMC12 |
| 2017 |
Beckmann, K., O'Callaghan, M., Ruseckaite, R., Kinnear, N., Miller, C., Evans, S., . . . Moretti, K. (2017). Prostate cancer outcomes for men who present with symptoms at diagnosis. BJU International, 119(6), 862-871. DOI Scopus6 WoS6 Europe PMC5 |
| 2017 |
O'Callaghan, M. E., Raymond, E., Campbell, J. M., Vincent, A. D., Beckmann, K., Roder, D., . . . Moretti, K. (2017). Patient-reported outcomes after radiation therapy in men with prostate cancer: a systematic review of prognostic tool accuracy and validity. International Journal of Radiation Oncology Biology Physics, 98(2), 318-337. DOI Scopus11 WoS10 Europe PMC8 |
| 2017 |
Campbell, J., Raymond, E., O'Callaghan, M., Vincent, A., Beckmann, K., Roder, D., . . . Moretti, K. (2017). Optimum tools for predicting clinical outcomes in prostate cancer patients undergoing radical prostatectomy: a systematic review of prognostic accuracy and validity. Journal of Urology, 197(4), 900. DOI WoS1 |
| 2017 |
Tabar, L., Chen, T. H. H., Hsu, C. Y., Wu, W. Y. Y., Yen, A. M. F., Chen, S. L. S., . . . Duffy, S. W. (2017). Evaluation issues in the swedish two-county trial of breast cancer screening: An historical review. Journal of Medical Screening, 24(1), 27-33. DOI Scopus12 WoS5 Europe PMC6 |
| 2016 |
Ruseckaite, R., Beckmann, K., O'Callaghan, M., Roder, D., Moretti, K., Millar, J., & Evans, S. (2016). A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: Trends in clinical presentation and management of the disease. BMC Cancer, 16(1), 11 pages. DOI Scopus24 WoS25 Europe PMC20 |
| 2016 |
Beckmann, K. R., Bennett, A., Young, G. P., Cole, S. R., Joshi, R., Adams, J., . . . Roder, D. (2016). Sociodemographic disparities in survival from colorectal cancer in South Australia: a population-wide data linkage study. BMC Health Services Research, 16(1), 1-14. DOI Scopus54 WoS50 Europe PMC42 |
| 2016 |
Ruseckaite, R., Beckmann, K., O'Callaghan, M., Roder, D., Moretti, K., Zalcberg, J., . . . Evans, S. (2016). Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset. BMC Research Notes, 9(1), 37. DOI Scopus5 Europe PMC4 |
| 2015 |
Beckmann, K., Lynch, J., Hiller, J., Farshid, G., Duffy, S., & Roder, D. (2015). Estimating over-diagnosis of breast cancer (Authors' Reply). International Journal of Cancer, 136(10), 2487. DOI Scopus1 WoS1 Europe PMC1 |
| 2015 |
Beckmann, K., Lynch, J., Hiller, J., Farshid, G., Houssami, N., Duffy, S., & Roder, D. (2015). A novel case-control design to estimate the extent of over-diagnosis of breast cancer due to organised population-based mammography screening. International Journal of Cancer, 136(6), 1411-1421. DOI Scopus30 WoS26 Europe PMC18 |
| 2015 |
Beckmann, K., Duffy, S., Lynch, J., Hiller, J., Farshid, G., & Roder, D. (2015). Estimates of over-diagnosis of breast cancer due to population-based mammography screening in South Australia after adjustment for lead time effects. Journal of medical screening, 22(3), 127-135. DOI Scopus27 WoS26 Europe PMC21 |
| 2014 |
Beckmann, K., Roder, D., Hiller, J., Farshid, G., & Lynch, J. (2014). Influence of mammographic screening on breast cancer incidence trends in South Australia. Asian Pacific Journal of Cancer Prevention (APJCP), 15(7), 3105-3112. DOI Scopus8 WoS3 Europe PMC6 |
| 2014 |
Beckmann, K., Bennett, A., Young, G., & Roder, D. (2014). Treatment patterns among colorectal cancer patients in South Australia: a demonstration of the utility of population-based data linkage. Journal of Evaluation in Clinical Practice, 20(4), 467-477. DOI Scopus32 WoS30 Europe PMC30 |
| 2013 |
Beckmann, K., Roder, D., Hiller, J., Farshid, G., & Lynch, J. (2013). Do breast cancer risk factors differ among those who do and do not undertake mammography screening?. Journal of Medical Screening, 20(4), 208-219. DOI Scopus16 WoS16 Europe PMC14 |
| 2013 |
Behm, E., Beckmann, K., Dahlstrom, J., Zhang, Y., Cho, C., Stuart-Harris, R., . . . Buckingham, J. (2013). Surgical margins and risk of locoregional recurrence in invasive breast cancer: An analysis of 10-year data from the Breast Cancer Treatment Quality Assurance Project. The Breast, 22(5), 839-844. DOI Scopus34 WoS32 Europe PMC22 |
| 2013 |
Beckmann, K., Farshid, G., Roder, D., Hiller, J., & Lynch, J. (2013). Impact of hormone replacement therapy use on mammographic screening outcomes. Cancer Causes & Control, 24(7), 1417-1426. DOI Scopus7 WoS7 Europe PMC6 |
| 2012 |
Dobbinson, S., Wakefield, M., Hill, D., Girgis, A., Aitken, J. F., Beckmann, K., . . . Bowles, K. A. (2012). Children's sun exposure and sun protection: Prevalence in Australia and related parental factors. Journal of the American Academy of Dermatology, 66(6), 938-947. DOI Scopus40 WoS32 Europe PMC25 |
| 2011 |
Beckmann, K. R., Buckingham, J., Craft, P., Dahlstrom, J. E., Zhang, Y., Roder, D., & Stuart Harris, R. (2011). Clinical characteristics and outcomes of bilateral breast cancer in an Australian cohort. The breast, 20(2), 158-164. DOI Scopus59 WoS56 Europe PMC45 |
| 2010 |
Craft, P., Buckingham, J., Dahlstrom, J., Beckmann, K., Zhang, Y., Stuart-Harris, R., . . . Tait, N. (2010). Variation in the management of early breast cancer in rural and metropolitan centres: Implications for the organisation of rural cancer services. The Breast, 19(5), 396-401. DOI Scopus41 WoS39 Europe PMC35 |
| 2009 |
Beckmann, K., Pinnock, C., Tamblyn, D., Kopsaftis, T., Stapleton, A., & Roder, D. (2009). Clinical and socio-demographic profile of an Australian multi-institutional prostate cancer cohort. Asia Pacific Journal of Clinical Oncology, 2009(5), 247-256. DOI Scopus12 WoS11 |
| 2009 |
Beckmann, K., Olver, I., Young, G., Roder, D., Foreman, L., & Wilson, B. (2009). Patient and carer perceptions of cancer care in South Australia. Australian Health Review, 33(4), 645-655. DOI Scopus3 WoS2 Europe PMC1 |
| 2008 |
Luke, C., Koczwara, B., Karapetis, C., Pittman, K., Price, T., Kotasek, D., . . . Roder, D. (2008). Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical care. Australian and New Zealand Journal of Public Health, 32(4), 383-389. DOI Scopus30 WoS31 Europe PMC26 |
| 2008 |
Roder, D., Houssami, N., Farshid, G., Gill, P., Luke, C., Downey, P., . . . Williamson, L. (2008). Population screening and intensity of screening are associated with reduced breast cancer mortality: evidence of efficacy of mamography screening in Australia. Breast Cancer Research and Treatment, Online(3), 1-2. DOI Scopus114 WoS105 Europe PMC75 |
| 2008 |
Shahid, S., Beckmann, K. R., & Thompson, S. (2008). Supporting cancer control for indigenous Australians: Initiatives and challenges for cancer councils. Australian health review, 32(1), 56-65. DOI Scopus14 WoS15 Europe PMC13 |
| 2008 |
Dobbinson, S., Wakefield, M., Hill, D., Girgis, A., Aitken, J. F., Beckmann, K., . . . Bowles, K. A. (2008). Prevalence and determinants of Australian adolescents' and adults' weekend sun protection and sunburn, summer 2003-2004. Journal of the American Academy of Dermatology, 59(4), 602-614. DOI Scopus125 WoS112 Europe PMC87 |
| 2008 |
Jones, S., Rayner, J., & Beckmann, K. (2008). Solaria compliance with the Australia/New Zealand Standard in Adelaide. Health Promotion Journal of Australia, 19(3), 222-225. DOI Scopus2 WoS2 Europe PMC1 |
| 2008 |
Jones, S. B. W., Beckmann, K., & Rayner, J. (2008). Australian primary schools' sun protection policy and practice: Evaluating the impact of the National Sunsmart Schools Program. Health Promotion Journal of Australia, 19(2), 86-90. DOI Scopus57 WoS56 Europe PMC38 |
| 2007 |
Scully, M., Dixon, H., White, V., & Beckmann, K. (2007). Dietary, physical activity and sedentary behaviour among Australian secondary students in 2005. Health Promotion International, 22(3), 236-245. DOI Scopus70 WoS68 Europe PMC51 |
| 2007 |
Abell, L., Beckmann, K., Strange, C., Leone, L., Kerrins, E., Lee, S., . . . Abram, L. (2007). Providing accommodation services for rural cancer patients: The experience in South Australia. Cancer Forum, 31(2), 98-104. Scopus1 WoS1 |
| 2007 |
Beckmann, K., Strassnick, K., Abell, L., Hermann, J., & Oakley, B. (2007). Is a Chronic Disease Self-Management Program beneficial to people affected by cancer?. Australian Journal of Primary Health, 13(1), 36-44. DOI Scopus12 WoS9 |
| 2003 |
Beckmann, K., Iosifidis, P., Shorne, L., Gilchrist, S., & Roder, D. (2003). Effects of variations in hysterectomy status on population coverage by cervical screening. Australian and New Zealand Journal of Public Health, 27(5), 507-512. DOI Scopus8 WoS6 Europe PMC5 |
| 2001 |
Beckmann, K. R., Kirke, B. A., McCaul, K. A., & Roder, D. M. (2001). Use of fake tanning lotions in the South Australian population. Medical Journal of Australia, 174(2), 75-78. DOI Scopus27 WoS21 Europe PMC15 |
| 1991 |
Litjens, T., Morris, C. P., Gibson, G. J., Beckmann, K. R., & Hopwood, J. J. (1991). Human N-acetylgalactosamine-4-sulphatase: Protein maturation and isolation of genomic clones. Biochemistry International, 24(2), 209-215. Scopus15 WoS14 Europe PMC10 |
| 1989 |
Occhiodoro, T., Beckmann, K. R., Morris, C. P., & Hopwood, J. J. (1989). Human α-L-fucosidase: Complete coding sequence form cDNA clones. Biochemical and Biophysical Research Communications, 164(1), 439-445. DOI Scopus43 WoS43 Europe PMC36 |
| 1989 |
Litjens, T., Baker, E. G., Beckmann, K. R., Morris, C. P., Hopwood, J. J., & Callen, D. F. (1989). Chromosomal localization of ARSB, the gene for human N-acetylgalactosamine-4-sulphatase. Human Genetics, 82(1), 67-68. DOI Scopus63 WoS52 Europe PMC39 |